Local recurrence of renal cell carcinoma (RCC) after definitive treatment remains a complex clinical scenario. Surgery, ablation, and radiotherapy may provide local disease control in selected patients, but evidence comparing these approaches is limited and outcomes appear to depend substantially on the characteristics of the initial disease.
A systematic review and meta-analysis evaluated the efficacy and safety of local salvage therapies for RCC recurrence following radical nephrectomy, partial nephrectomy, or ablation.
The study, titled “Salvage therapies for local recurrence of renal cell carcinoma: a systematic review and meta-analysis,” was published on August 16, 2026, in World Journal of Urology.
Authors: Agata Suleja, Ahmed R. Alfarhan, Marcin Miszczyk, Riccardo Campi, Hussain Albin Hamdhah, Daniele Amparore, Giulio Francolini, Navid Roessler, Keiichiro Miyajima, Shota Inoue, Felix Lübbersmeyer, Abdulrahman A. Alhazeem, Paweł Rajwa, Axel Bex, Alessandro Volpe, Piet Ost, and Shahrokh F. Shariat.
What Did the Study Evaluate?
The review included 47 studies comprising 2,039 patients treated with definitive local salvage therapy for isolated RCC recurrence. Patients with synchronous distant metastases were excluded. The primary outcome was recurrence-free survival (RFS), with overall survival (OS), cancer-specific survival (CSS), and serious grade ≥3 adverse events evaluated as secondary outcomes.
The evidence was predominantly retrospective: 45 studies were retrospective, one was a prospective registry, and one was a single-arm phase 2 study. Importantly, pooled analyses were stratified according to primary treatment and salvage modality, with no pooling across the dataset as a whole and no statistical comparison between subgroups.
Recurrence After Radical Nephrectomy
Recurrence after radical nephrectomy was associated with the least favorable outcomes. Twelve studies involving 564 patients evaluated salvage surgery in this setting. Across seven studies with available RFS data, pooled 3-year RFS was 38% (95% CI, 30%–47%), with distant metastatic progression representing the predominant pattern of failure. Pooled 5-year OS was 62%, while 5-year CSS was 61%.
These patients frequently had more advanced disease at initial treatment, with pT3–4 tumors reported in 27% to 69% of patients across individual studies. The authors therefore emphasized that the high rate of subsequent progression likely reflects, at least in part, the underlying biology of the primary disease.
Recurrence After Partial Nephrectomy
Patients recurring after partial nephrectomy generally had lower-stage primary tumors, most commonly pT1 disease. Nine studies involving 410 patients evaluated surgical salvage with repeat partial or radical nephrectomy. In the only study reporting RFS as a time-to-event outcome, 3-year RFS was 78% and 5-year RFS was 76%.
However, results varied substantially across studies, from relatively low rates of recurrence to cohorts in which distant metastatic progression accounted for a large proportion of subsequent failures. Salvage ablation was also evaluated after partial nephrectomy. Across two studies with available time-to-event data, pooled 3-year RFS was 69% (95% CI, 49%–84%).
Surgery or Ablation After Partial Nephrectomy?
Available comparative data did not demonstrate a clear oncologic advantage for one local approach. In one study, salvage partial nephrectomy and radical nephrectomy showed no significant differences in local recurrence-free survival or RFS. Partial nephrectomy, however, resulted in better preservation of renal function.
Similarly, a comparison of percutaneous ablation with surgical resection found no significant differences in disease recurrence, local control, or distant metastases. Ablation was associated with fewer postoperative complications, 5% versus 41%, as well as better renal function preservation. These findings were derived from observational studies and therefore cannot establish superiority of one strategy.
What About Recurrence After Primary Ablation?
Repeat ablation showed favorable outcomes after failure of primary ablation. Six studies involving 193 patients evaluated this strategy, with pooled 3-year RFS of 71% (95% CI, 45%–88%; n=105).
Salvage surgery after primary ablation was evaluated in only 48 patients. Although recurrence rates were relatively low during short follow-up, the pooled rate of severe complications was 19%, the highest among the evaluated salvage groups. The authors noted that operating in previously ablated tissue may be technically challenging because of perinephric fibrosis and altered anatomy.
The Role of Radiotherapy
Evidence supporting radiotherapy in the salvage setting remains limited. Three studies involving 101 patients evaluated radiotherapy after previous surgery, with heterogeneous treatment approaches and outcomes. A small prospective study combining stereotactic radiotherapy with sintilimab and axitinib reported a 2-year local control rate of 100% and 2-year PFS of 91.5%, although grade ≥3 adverse events occurred in 50% of patients.
While stereotactic body radiotherapy represents an emerging non-invasive option, the authors emphasized that dedicated prospective evidence in locally recurrent RCC remains limited.
Can Local Therapy Delay Systemic Treatment?
One propensity score-matched analysis compared local treatment, consisting of surgery or SBRT, with systemic therapy alone. Median PFS was significantly longer with local therapy, at 23.9 versus 7.5 months (p=0.001). However, the difference in 2-year OS was not statistically significant, at 91.6% versus 71.8% (p=0.084).
Within the local treatment group, no significant differences in PFS or OS were observed between surgery and SBRT. Given the observational design and potential for patient-selection bias, these findings do not establish superiority of local treatment over systemic therapy.
Why the Initial Treatment Matters
A key finding of the analysis was that outcomes differed substantially according to the treatment used for the primary RCC. Patients initially managed with partial nephrectomy or ablation generally had smaller, lower-stage tumors. In contrast, those treated with radical nephrectomy more frequently had locally advanced disease and a higher baseline risk of subsequent distant progression.
The apparently more favorable outcomes after recurrence following partial nephrectomy or ablation should therefore not be interpreted as comparisons between salvage modalities. Rather, the differences reflect, at least in part, confounding by indication and differences in underlying disease biology.
Limitations
The overall quality of evidence was low. Most studies were retrospective, no randomized controlled trials were available, and patient selection represented an important source of bias. There was also substantial heterogeneity in recurrence definitions, patient characteristics, treatment techniques, endpoints, and follow-up.
Several studies, particularly those evaluating ablation, were small or available only as conference abstracts. In addition, evolving systemic treatment, including adjuvant immunotherapy, may change the clinical context in which contemporary RCC recurrence is managed.
What Is the Takeaway?
Local salvage therapy can provide meaningful disease control in selected patients with recurrent RCC, but outcomes vary substantially according to the primary treatment and underlying disease characteristics.
Repeat ablation showed favorable outcomes after recurrence following primary ablation, while recurrence after partial nephrectomy could be managed with either repeat surgery or ablation, although outcomes were heterogeneous. In contrast, patients recurring after radical nephrectomy had the least favorable prognosis, with approximately two-thirds experiencing progression within three years, predominantly due to distant metastases.
These differences should not be interpreted as evidence that one salvage modality is superior to another, as they are strongly influenced by patient selection, primary tumor stage, and confounding by indication.
The authors emphasized that locally recurrent RCC requires multidisciplinary management and highlighted the need for expert consensus on quality indicators, prospective multicenter registries, and standardized outcome reporting to better define optimal treatment strategies.
The full article is available in World Journal of Urology.
Find more videos on OncoDaily YouTube TV.